| Comprehensive Online Oncology Database | |
|
New Drug Development Status Table
Note: Report links have been disabled for this sample screen.
| SUBSCRIBER SEARCH | ||||||||
|
|
REPORT FORMAT New Drug Development Status Table Note: Report links have been disabled for this sample screen. |
|
|||||||||||||
| 1-949-830-0448 | info@newmedinc.com | ||||||||||||||
Your search found 7 records. Click on a developer link to see more information.
| Developer | Designation | Description | Development Status & Location - Indications |
|
Access Pharmaceuticals
Current as of: December 04, 2007 | Brand Name: ProLindac Other Designation: AP5346 | AP5346 is a soluble, synthetic, platinum-polymer complex with a mean molecular weight of 20 kD, designed to deliver high concentrations of diaminocyclohexane (DACH) platinum directly to solid tumors; oxaliplatin prodrug. | Phase I (begin 4/03, completed 4/05) Europe (France, Netherlands), USA - solid tumors, advanced, refractory Phase II (begin 6/06, ongoing 10/07) Europe - ovarian cancer, recurrent Phase I/II (ongoing 12/05) USA (combination) - colorectal cancer Phase II (begin 2/06) USA - head and neck cancer |
|
AEterna Zentaris
Current as of: December 04, 2007 | Generic Name: Perifosine Other Designation: KRX-0401, D-21266 | Perifosine, a novel heterocyclic alkylphospholipid (alkylphosphocholine derivative) analog of hexadecylphosphocholine (miltefosine), is an oral Akt inhibitor that activates the MAP kinase (MEK/ERK) pathway leading to the activation of p21 independently of p53. Administration Route: PO | Phase I (begin 7/96, ongoing 5/99) Europe (Germany), phase I (begin 2/99, completed 5/04) USA, phase I (begin 2/00, completed 12/03) USA, phase I (completed 6/04) Europe (Netherlands) (combination), phase I (begin 11/04, closed 12/06) USA (combination), phase I (begin 8/04, ongoing 1/06) USA (combination), phase I (begin 10/06, ongoing 11/07) USA; phase IIa (begin 1/05, ongoing 11/07) USA - solid tumors, advanced, refractory Phase II (begin 7/03, completed 9/05) USA, phase II (begin 8/03, suspended 4/04) Canada - pancreatic cancer, locally advanced or metastatic adenocarcinoma, advanced, pancreatic Phase II (begin 3/03, closed 6/05) USA, phase II (begin 4/03, completed 3/05) USA - prostate cancer, hormone-sensitive, biochemically recurrent prostate cancer, metastatic, androgen-independent Phase II (begin 6/03, closed 6/05) Canada, phase II (begin 5/05, ongoing 1/06) USA (combination) - breast cancer, locally advanced or metastatic, recurrent or refractory, Er or Pr positive Phase II (begin 6/03, closed 3/04) USA, phase II (begin 6/03, suspended 4/04) Canada; phase II (begin 12/06, ongoing 11/07) - sarcoma, soft tissue, locally advanced or metastatic Phase II (begin 6/03, completed 12/05) Canada - melanoma, metastatic or recurrent, first line Phase II (begin 5/03, completed 7/04) USA - head and neck cancer, metastatic or recurrent Phase I/II (begin 9/04, ongoing 11/07) USA; phase II (begin 9/05, closed 11/07) (multimodality) Europe (Netherlands) - non-small cell lung cancer (nsclc), refractory Phase I/II (begin 8/06, ongoing 12/06) USA (combination); phase II (begin 1/06, closed 10/07) USA (combination); phase I (begin 12/06, ongoing 2/07) USA (combination) - multiple myeloma, relapsed or refractory Phase I (begin 3/06, ongoing 2/07) USA (combination) - chronic myelogenous leukemia (CML) Phase II (begin 10/06, ongoing 11/07) USA - glioma, malignant, recurrent or progressive glioblastoma multiforme, recurrent, malignant Phase II (begin 8/05, ongoing 11/07) USA - solid tumors, metastatic Phase I (begin 10/06, ongoing 11/07) USA (combination), phase I (begin 10/06, ongoing 11/07) USA (combination); phase II (begin 3/07, ongoing 11/07) USA; phase II (begin 7/07, ongoing 11/07) USA - renal cell carcinoma (RCC), advanced gastrointestinal stromal tumors (GIST), advanced hepatocellular carcinoma (HCC), advanced |
|
Allos Therapeutics
Current as of: December 04, 2007 | Other Designation: RH1, RH-1 | RH1, a novel diaziridinylbenzoquinone, is a targeted cytotoxic prodrug bioactivated by the enzyme DT-diaphorase (DTD), which is overexpressed in many tumors relative to normal tissue. Administration Route: intravenous (IV) | Phase I (begin 9/03, completed 6/06) Europe (UK); phase I (begin 11/07) USA - solid tumors, advanced, refractory
non-Hodgkin's lymphoma (NHL), advanced, refractory or relapsed Phase I (begin 11/07) USA - solid tumors, advanced, refractory non-Hodgkin's lymphoma (NHL), advanced, refractory |
|
ArQule
Current as of: December 03, 2007 | Other Designation: ARQ-650RP ARQ 650RP ARQ 197 ARQ197 | ARQ 197 an orally administered, proprietary small molecule c-Met inhibitor is the lead compound of a series of proprietary compounds generated through ArQules Cancer Survival Protein (CSP) modulation program. Administration Route: PO | Phase I (begin 2/06, closed 1/07, completed 6/07) USA - solid tumors, metastatic, refractory - pancreatic cancer, inoperable, locally advanced or metastatic, first line Phase II (begin 10/07) USA - microphthalmia transcription factor associated (MiT) tumors, inoperable locally advanced or metastatic |
|
Athersys
Current as of: December 04, 2007 | Brand Name: MultiStem | MultiStem is being developed for bone marrow transplantation/ oncology support as well as ischemic stroke and other indications. Administration Route: intravenous (IV) ex vivo | IND (approved 11/07) USA - hematologic malignancies |
|
Aveo Pharmaceuticals Current as of: December 03, 2007 | Other Designation: AV-951 | AV-951 is a novel, highly potent and specific inhibitor of vascular endothelial growth factor receptors VEGFr1, VEGFr2, and VEGFr3. Administration Route: PO | Phase I (closed 07) USA - solid tumor, advanced Phase II (begin 10/07) Europe (Russia), India; phase I (closed 11/07) USA (combination) - renal cell carcinoma (RCC), advanced renal cell carcinoma (RCC), recurrent or metastatic, second line |
|
Callisto Pharmaceuticals
Current as of: December 04, 2007 | Generic Name: Azaspirane Brand Name: Atiprimod | Atiprimod is a macrophage-targeting oral cytokine inhibitor with antiangiogenic properties. Administration Route: PO | Phase I/IIa (begin 5/04, ongoing 4/07) USA - multiple myeloma, refractory or relapsed Phase I/II (begin 3/05, closed 12/06) USA - solid tumors, advanced hematologic malignancies, advanced Phase I (planned 4/07) USA - myelodysplastic syndrome (MDS) Phase II (begin 11/06, ongoing 10/07) USA - carcinoid tumors, advanced |
| HOME | NEW MEDICINE | SITE MAP |
NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE: 1-949-830-0448 FAX: 1-949-830-0887
INFO@NEWMEDINC.COM